Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated by sevelamer hydrochloride

Renal Failure

Volumn 27, Issue 2, 2005, Pages 143-147

  Sonikian, Macroui A ^a   Pani, Ioanna T ^a   Iliopoulos, Anastasios N ^a   Koutala, Kaliopi G ^a   Marioli, Stamatia I ^a   Vlassopoulos, Dimosthenis A ^a  

^a AMALIA FLEMING GENERAL HOSPITAL   (Greece)

Author keywords

Aluminum; Calcium carbonate; Metabolic acidosis; Parathyroid hormone; Serum potassium; Sevelamer hydrochloride

Indexed keywords

ALUMINUM; ALUMINUM HYDROXIDE; CALCIUM; CALCIUM CARBONATE; PHOSPHATE BINDING AGENT; POTASSIUM; SEVELAMER;

ACID BASE BALANCE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIALYSIS; DOSE RESPONSE; FEMALE; HEMODIALYSIS; HUMAN; HYPERKALEMIA; MALE; METABOLIC ACIDOSIS; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT;

ACIDOSIS; AGED; CALCIUM; CASE-CONTROL STUDIES; EPOXY COMPOUNDS; FEMALE; HUMANS; HYPERKALEMIA; MALE; MIDDLE AGED; PHOSPHATE-BINDING PROTEINS; PHOSPHORUS; POLYAMINES; POLYETHYLENES; POTASSIUM; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 15344349987     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-200048238     Document Type: Article

References (23)

1. Burke, S.K.; Slatopolski, E.A.; Goldberg, D.I. A novel calcium- and aluminum-free phosphate binder inhibits phosphate absorption in normal volunteers. Nephrol. Dial. Transplant. 1997, 12, 1640-1644.
2. Chertow, G.M.; Burke, K.; Lazarus, J.M.; et al. Polyallylamine hydrochloride (Renagel). A non-calcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am. J. Kidney Dis. 1997, 29, 66-71.
3. Alfrey, A.C. Aluminium toxicity in patients with chronic renal failure. Ther. Drug Monit. 1993, 15, 593-597.
4. 3): an efficient and safe phosphate binder in hemodialysis patients? A 3-year study. Nephrol. Dial. Transplant. 1993, 8, 530-534.
5. Clarkson, E.M.; McDonald, S.J.; de Wardener, H.E. Effect of high calcium carbonate in normal subjects and patients with chronic renal failure. Clin. Sci. 1966, 30, 425-428.
6. Marco, M.P.; Muray, S.; Betriu, A.; Craver, L.; Belart, M.; Fernandez, E. Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients. Nephron 2002, 92, 499-500.
7. Brenes, L.G.; Brenes, J.N.; Hernadez, M.M. Familial proximal renal tubular acidosis. A distinct clinical entity. Am. J. Med. 1977, 63, 244-252.
8. Mitchell, J.H.; Wildenthal, K.; Johnson, R.L. The effects of acid-base disturbances on cardiovascular and pulmonary function. Kidney Int. 1972, 1, 375-389.
9. Turnbull, A.D.; Dobell, A.R.C. The effect of pH change on the ventricular fibrilation threshold. Surgery 1966, 60, 1040-1043.
10. Adrogué, H.J.; Madias, N.E. Changes in serum potassium concentration during acute acid-base disturbances. Am. J. Med. 1981, 71, 456-467.
11. Bushinsky, D.A. The contribution of acidosis to renal osteodystrophy. Kidney Int. 1995, 47, 1816-1832.
12. 2-microglobulin generation: in vivo and in vitro studies. J. Am. Soc. Nephrol. 1996, 7, 350-356.
13. Chertow, G.M.; Burke, S.K.; Dillon, M.A.; Slatopolski, E.A.; Renagel® Study Group. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of hemodialysis patients. Nephrol. Dial. Transplant. 1999,14, 2907-2914.
14. Goldberg, D.I.; Dillon, M.A.; Slatopolski, E.A.; et al. Effect of Renagel®, a nonabsorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium and intact parathyroid hormone in end-stage renal disease patients. Nephrol. Dial. Transplant. 1998, 13, 2303-2310.
15. Borras, M.; Marco, M.P.; Fernandez, E. Treatment with sevelamer decreases bicarbonate levels in peritoneal dialysis patients. Perit. Dial. Int. 2002, 22, 737-738.
16. Galliern, M.; Cozzolino, M.; Brancaccio, D. Transient decrease of serum bicarbonate levels with sevelamer hydrochloride as the phosphate binder. Kidney Int. 2000, 57, 1776-1777.
17. Sadec, T.; Mazouz, H.; Bahloul, H.; et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs. calcium carbonate in dialysis patients: an open label, randomized study. Nephrol. Dial. Transplant. 2003, 18, 582-589.
18. Čižman, B. Hyperphosphatemia and treatment with sevelamer in haemodialysis patients. Nephrol. Dial. Transplant. 2003, 18 (Suppl 5), 47-49.
19. Wilkes, B.M.; Reiner, D.; Kern, M.; Burke, S. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (Renagel) in dialysis patients. Clin. Nephrol. 1998, 50, 381-386.
20. Chertow, G.M.; Dillon, M.A.; Burke, S.K.; Slatopolsky, E. A randomized trial of sevelamer hydrochloride (Renagel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin. Nephrol. 1999, 51, 18-26.
21. Slatopolski, E.A.; Burke, S.K.; Dillon, M.A.; Renagel® Study Group. Renagel, a nonabsorbed calcium- and aluminium-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int. 1999, 10, 1274-1280.
22. Bleyer, A.J.; Burke, S.K.; Dillon, M.A.; et al. Comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am. J. Kidney Dis. 1999, 33, 694-701.
23. Drüeke, T.B. Foreword: extraskeletal calcifications in patients with chronic renal failure. Nephrol. Dial. Transplant. 2002, 17, 330-331.